Literature DB >> 10563423

Epidemiology of primary CNS lymphoma.

M Schabet1.   

Abstract

In the beginning of the nineties the National Cancer Institute Surveillance, Epidemiology, and End Results Program calculated the incidence of primary central nervous system non-Hodgkin's lymphoma (PCNSL) as 1:100000. The incidence of PCNSL has been increasing since the seventies in immunocompetent patients. The main increase, however, is taking place since the mid-eighties and is due to the increase of immunodeficiency and immunosuppression. The risk is 2-6% in AIDS patients according to clinical data and will probably further increase with the length of survival in these patients. Transplant patients carry a risk of 1-5% to develop a PCNSL. The risk is 1-2% for renal, and 2-7% for cardiac, lung or liver transplant recipients. Patients with congenital immune deficiency have a risk of 4%. PCNSL may also present as a secondary malignancy.

Entities:  

Mesh:

Year:  1999        PMID: 10563423     DOI: 10.1023/a:1006290032052

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.

Authors:  M Reni; A J Ferreri; M P Garancini; E Villa
Journal:  Ann Oncol       Date:  1997-03       Impact factor: 32.976

2.  Posttransplantation de novo tumors in liver allograft recipients.

Authors:  I Penn
Journal:  Liver Transpl Surg       Date:  1996-01

3.  Epstein-Barr virus in AIDS-related primary central nervous system lymphoma.

Authors:  E M MacMahon; J D Glass; S D Hayward; R B Mann; P S Becker; P Charache; J C McArthur; R F Ambinder
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

4.  The impact of primary central nervous system lymphoma in AIDS patients: a population-based autopsy study from Oslo.

Authors:  A K Goplen; O Dunlop; K Liestøl; O C Lingjaerde; J N Bruun; J Maehlen
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-04-01

5.  Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

Authors:  C Confavreux; P Saddier; J Grimaud; T Moreau; P Adeleine; G Aimard
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

6.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

Review 7.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

8.  Central nervous system lymphomas in organ allograft recipients.

Authors:  I Penn; G Porat
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

9.  Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome.

Authors:  J E Baumgartner; J R Rachlin; J H Beckstead; T C Meeker; R M Levy; W M Wara; M L Rosenblum
Journal:  J Neurosurg       Date:  1990-08       Impact factor: 5.115

10.  Primary central nervous system lymphoma as a secondary malignancy.

Authors:  L M DeAngelis
Journal:  Cancer       Date:  1991-03-01       Impact factor: 6.860

View more
  67 in total

1.  Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma.

Authors:  Keisuke Kimura; Yoshihiko Usui; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2012-06-05       Impact factor: 2.447

2.  IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas.

Authors:  Hema L Ramkumar; De Fen Shen; Jingsheng Tuo; Rita M Braziel; Sarah E Coupland; Justine R Smith; Chi-Chao Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-25       Impact factor: 3.117

Review 3.  Management of primary intraocular lymphoma.

Authors:  Stella K Kim; Chi-Chao Chan; Dana J Wallace
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

4.  Primary testicular and intraocular lymphomas: two case reports and a review of the literature.

Authors:  Dana J Wallace; Chandra R Altemare; De Fen Shen; Marc D deSmet; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 6.048

Review 5.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

6.  Radiotherapy of indolent orbital lymphomas : Two radiation concepts.

Authors:  Laila König; Robert Stade; Juliane Rieber; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2016-05-09       Impact factor: 3.621

7.  Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.

Authors:  Samir Dalia; Peter Forsyth; Julio Chavez; Samantha Price; Bijal Shah; Celeste Bello; Lubomir Sokol; Edward Pan; Eduardo Sotomayor; Ji-Hyun Lee; Kate Fisher; Michael Jaglal
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

8.  Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Kohji Nishida
Journal:  Transl Vis Sci Technol       Date:  2012-10-22       Impact factor: 3.283

Review 9.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 10.  Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.

Authors:  James Rubenstein; Andrés J M Ferreri; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.